Draft guide attempts to ease pharma worries over EMA-HTA advice
This article was originally published in SRA
Executive Summary
The European Medicines Agency has released for consultation a draft guidance that seeks to boost the use of the parallel scientific advice procedure that the agency and national health technology (HTA) bodies offer drug companies1.